New Line Medicines Private Limited
About New Line Medicines Private Limited
Data last updated:
New Line Medicines Private Limited is a private limited company based in Chilakaluripet, Andhra Pradesh, India. It operates in the manufacturing segment of the chemicals sector. It was incorporated on 19 March 2016 and has been in existence for over 10 years.
The company is registered with the Registrar of Companies (ROC), Vijayawada, under CIN U24100AP2016PTC098568.
The company has an authorised share capital of ₹60 Lakh and a paid-up capital of ₹31 Lakh. It is led by directors Komala Devi Vankayalapati and Srinivasa Rao Vankayalapati.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Door No : 1 – 1089 N T R Colony, Chilakaluripet, Andhra Pradesh, India – 522616.
As per the financials filed for FY 2025, the company reported a revenue of ₹13,700, a growth of 1% compared to the previous year. For the same year it recorded a net profit of ₹1,400 (net margin 10.2%) and EBITDA of ₹1,900 (EBITDA margin 13.9%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
New Line Medicines Private Limited's registered office is in Chilakaluripet, Andhra Pradesh. Its e-mail address is in the company report.
- Email
- Registered AddressDoor No : 1 – 1089 N T R Colony, Chilakaluripet, Andhra Pradesh, India – 522616
- IndustryChemicals, Manufacturing, Basic Chemical
To see the full contact details of New Line Medicines Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of New Line Medicines Private Limited
FY 2025 filings availableNew Line Medicines Private Limited reported revenue of ₹13,700 (up 1% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 2% over three years, including 1% growth in the latest year. EBITDA rose 12% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1,900 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1,400 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 13.9% | ||||
| Net Profit Margin | 10.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of New Line Medicines Private Limited, buy the company report.
Board of directors of New Line Medicines Private Limited
New Line Medicines has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Komala Devi Vankayalapati | Director | 19 Mar 2016 | 10 Years 7 Months | Current |
| Srinivasa Rao Vankayalapati | Director | 19 Mar 2016 | 10 Years 7 Months | Current |
Legal cases
No court or tribunal cases involving New Line Medicines Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for New Line Medicines Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for New Line Medicines Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
New Line Medicines Private Limited has 2 board changes on record since 2016: 2 appointments. The latest: Komala Devi Vankayalapati was appointed as Director on 19 Mar 2016.
Frequently asked questions
New Line Medicines is an active private limited company based in Chilakaluripet, Andhra Pradesh, India. The company works in manufacturing, within the chemicals industry. It was incorporated on 19 March 2016 (10+ years old) and is registered under CIN U24100AP2016PTC098568.
New Line Medicines has 2 current directors:
- Komala Devi Vankayalapati - Director
- Srinivasa Rao Vankayalapati - Director
The latest financial statements of New Line Medicines on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2016 are in the company report.
The CIN (Corporate Identification Number) of New Line Medicines is U24100AP2016PTC098568. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
New Line Medicines was incorporated on 19 March 2016, making it 10+ years old. It is registered with the Registrar of Companies, Vijayawada.
Komala Devi Vankayalapati was appointed as Director on 19 Mar 2016. Srinivasa Rao Vankayalapati was appointed as Director on 19 Mar 2016.
The registered office of New Line Medicines is at Door No : 1 – 1089 N T R Colony, Chilakaluripet, Andhra Pradesh, India – 522616.
New Line Medicines operates in the chemicals industry, in the manufacturing segment.
The compliance status of New Line Medicines is compliant as of 21 August 2026. The company is actively filing with the Registrar of Companies.
New Line Medicines can be reached at its registered office: Door No : 1 – 1089 N T R Colony, Chilakaluripet, Andhra Pradesh, India – 522616.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
